XML 73 R47.htm IDEA: XBRL DOCUMENT v3.25.1
Income Taxes - Additional Information (Detail) - USD ($)
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Income Taxes Disclosure [Line Items]      
Income tax benefit $ 0 $ 0  
Net capitalized R&D deferred tax assets 66,678,000 66,678,000  
Net deferred tax assets before the valuation allowance 173,000,000 141,800,000  
Unrecognized tax benefits $ 0 0  
Open tax year 2020 2021 2022 2023 2024    
Zafgen [Member]      
Income Taxes Disclosure [Line Items]      
Net operating loss carryforwards $ 33,500,000    
Net capitalized R&D deferred tax assets $ 66,900,000    
Net capitalized R&D deferred tax assets realization description is subject to the built-in loss rules under Section 382 and may not be realized if the underlying asset associated with the R&D is disposed within five years of the Merger, or May 28, 2025    
Net operating loss carryforwards, change in ownership, annual utilization limit $ 35,000    
Domestic Tax Authority [Member]      
Income Taxes Disclosure [Line Items]      
Net operating loss carryforwards $ 198,200,000    
Net operating loss carryforwards, beginning of expiration period 2026    
Domestic Tax Authority [Member] | No Expiration [Member]      
Income Taxes Disclosure [Line Items]      
Net operating loss carryforwards $ 159,500,000    
Operating loss carryforwards, minimum percentage of taxable income in tax period 80.00%    
Operating loss carryforwards, description carryforwards are limited to 80% of the taxable income in any one tax period.    
Foreign Tax Authority [Member]      
Income Taxes Disclosure [Line Items]      
Net operating loss carryforwards $ 1,200,000    
State and Local Jurisdiction [Member]      
Income Taxes Disclosure [Line Items]      
Net operating loss carryforwards $ 164,500,000    
Net operating loss carryforwards, beginning of expiration period 2030    
Federal and State [Member]      
Income Taxes Disclosure [Line Items]      
Tax credit carryforward $ 28,000,000    
Research and development tax credit carry forwards, beginning of expiration period 2039    
IRC Section 174 [Member]      
Income Taxes Disclosure [Line Items]      
Capitalization of research and development costs $ 69,200,000 $ 24,500,000 $ 22,200,000
IRC Section 174 [Member] | Performed in US [Member]      
Income Taxes Disclosure [Line Items]      
Capitalized research and development amortization period 5 years    
IRC Section 174 [Member] | Performed outside US [Member]      
Income Taxes Disclosure [Line Items]      
Capitalized research and development amortization period 15 years